Therapeutic effect of anti-inflammatory tripeptide KdPT on ophthalmoxerosis in mice

WANG Hua; XU Yuansheng; SONG Yan

doi:10.11665/j.issn.1000-5048.20210114

Journal of China Pharmaceutical University > 2021 > 52(1): 100-103. > DOI: 10.11665/j.issn.1000-5048.20210114

WANG Hua, XU Yuansheng, SONG Yan. Therapeutic effect of anti-inflammatory tripeptide KdPT on ophthalmoxerosis in mice[J]. Journal of China Pharmaceutical University, 2021, 52(1): 100-103. DOI: 10.11665/j.issn.1000-5048.20210114

Citation:

PDF (1500 KB)

Therapeutic effect of anti-inflammatory tripeptide KdPT on ophthalmoxerosis in mice

Guangzhou Link Health Pharma Co., Ltd., Guangzhou 510663, China

More Information

Received Date: October 21, 2020
Revised Date: December 16, 2020

Graphical Abstract

Abstract

Abstract

This study was designed to investigate the therapeutic effect of anti-inflammatory tripeptide KdPT on ophthalmoxerosis. Male BALB/c mice, 8-week old, were treated with 0.2% benzalkonium chloride solution to establish the ophthalmoxerosis model. Four weeks after modeling, the mice were randomly divided into control group, positive group and the low, medium, high dose groups of KdPT. Each group was given normal saline, artificial tears and 1, 10, 100 μg/mL KdPT, respectively. After 3, 5, 7, 10 and 14 days of treatment, the morphology of the eye surface was observed, and the fluorescein sodium staining score was performed. The amount of tear secretion was measured by phenol red cotton thread and the right corneas were taken out for histopathological analysis after 14 days of treatment. Data showed that there was no significant abnormality in general state and the weight of mice in each group at each time point of treatment. After 14 days of treatment, KdPT can promote the secretion of tear, repair the damaged corneal epithelium, and showed a significant therapeutic effect on ophthalmoxerosis in mice. Based on the data, it is possible for KdPT to be developed as a novel drug for ophthalmoxerosis.
- ophthalmoxerosis,
- tripeptide,
- KdPT,
- sodium fluorescein staining,
- tear secretion

FullText(HTML)

References (16)

References

[1]	.Chin J Ophthalmol， 2013，49（1）： 73-75.
[2]	Liu ZG， Yang WZ. Dry eye and its pathogenesis［J］. Ophthalmol CHN. 2005，14（5）： 343-345.
[3]	Wei Y， Asbell PA. The core mechanism of dry eye disease is inflammation［J］. Eye Contact Lens， 2014， 40（4）： 248-256.
[4]	Yamaguchi T. Inflammatory response in dry eye［J］. Invest Ophthalmol Vis Sci， 2018， 59（14）： DES192-DES199.
[5]	Jung HH， Ji YS， Sung MS， et al. Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with Sj?gren's syndrome［J］. Chonnam Med J， 2015， 51（1）： 26-32.
[6]	de Paiva CS， Pflugfelder SC， Ng SM， et al. Topical cyclosporine A therapy for dry eye syndrome［J］. Cochrane Database Syst Rev， 2019， 9： CD010051.
[7]	Pavan J， Lukenda A， Stambuk N， et al. Effects of alpha-MSH on corneal epithelial lesions in rats［J］. Coll Antropol， 2012， 36（4）： 1407-1411.
[8]	Ru YS， Huang Y， Liu HJ， et al. Α-Melanocyte-stimulating hormone ameliorates ocular surface dysfunctions and lesions in a scopolamine-induced dry eye model via PKA-CREB and MEK-Erk pathways［J］. Sci Rep， 2015， 5： 18619.
[9]	Dou ZX， Ru YS， Liu HJ. Combinatorial protective effects of α-melanocyte-stimulating hormone and carboxymethylcellulose on ocular surface in dry eye rat model［J］. Chin J Exp Ophthalmol（中华实验眼科杂志），2017，35（6）： 498-505.
[10]	Bettenworth D， Buyse M， B?hm M， et al. The tripeptide KdPT protects from intestinal inflammation and maintains intestinal barrier function［J］. Am J Pathol， 2011， 179（3）： 1230-1242.
[11]	Kucharzik T， Lemmnitz G， Abels C， et al. Mo1216 tripeptide KdPT accelerates disease remission in patients with mild to moderate active ulcerative colitis［J］. Gastroenterology， 2014， 146（5）： S-588.
[12]	Li CJ， Ge H， Cui LJ， et al. Molecular mechanism of action of K（D）PT as an IL-1RI antagonist for the treatment of rhinitis［J］. RSC Adv， 2014，4（89）： 48741-48749.
[13]	Mykicki N， Klenner L， Baumann C， et al. The tripeptide KdPT ameliorates ongoing psoriasis-like skin inflammation in murine and human skin［J］. Exp Dermatol， 2017， 26（4）： 328-334.
[14]	Narayanan S， Corrales RM， Farley W， et al. Interleukin-1 receptor-1-deficient mice show attenuated production of ocular surface inflammatory cytokines in experimental dry eye［J］. Cornea， 2008， 27（7）： 811-817.
[15]	Yamada A， Arakaki R， Kudo Y， et al. Targeting IL-1 in Sj?gren's syndrome［J］. Expert Opin Ther Targets， 2013， 17（4）： 393-401.
[16]	Vijmasi T， Chen FY， Chen YT， et al. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease［J］. Mol Vis， 2013， 19： 1957-1965.

Cited By

Get Citation

PDF

XML

Article views (152) PDF downloads (811)

Turn off MathJax

Article Contents

Abstract

References

Therapeutic effect of anti-inflammatory tripeptide KdPT on ophthalmoxerosis in mice

Abstract

References

Catalog

Export File

Citation

Format

Content